Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zolpidem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.85 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.85 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.85 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.85 |
| ▸ | ALB | P02768 | 2/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.85 |
| ▸ | HPGD | P15428 | 1/20 | 0.85 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.85 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | TSPO | P30536 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolpidem SCHEMBL17004049 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL8207467 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL40721 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL1402195 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL30604720 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL7127421 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL17477 | 1.00 | GABRB2 (0.85) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL7575406 | 0.99 | GABRB2 (0.83) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL876109 | 0.99 | GABRB2 (0.83) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Zolpidem SCHEMBL22685033 | 0.99 | GABRB2 (0.83) | GABRB2GABRA1ALBOPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20230317229-A1 | MULTI-STAGE RELEASE CANNABINOID COMPOSITIONS | Green Sky Creations LLC (US) | 2023-10-05 | — | — | US | claimed |
| US-20260139249-A1 | GENE REPLACEMENT THERAPY FOR FOXG1 SYNDROME | UNIVERSITY OF MASSACHUSETTS (US) | 2026-05-21 | — | — | US | disclosed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12606825-B2 | — | — | 2026-04-21 | — | — | US | disclosed |
| US-12570997-B2 | Factor H vectors and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4698653-A2 | NEURON SPECIFIC PROMOTERS FOR AAV GENE TRANSFER | University of Massachusetts (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12553036-B2 | GM3 synthase vectors and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2026-02-17 | — | — | US | disclosed |
| US-12553063-B2 | CAS13 family AAV vectors and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027068-A1 | METHODS OF ADMINISTERING R-KETAMINE | PERCEPTION NEUROSCIENCE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20220162641-A1 | FACTOR H VECTORS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162571-A1 | GM3 SYNTHASE VECTORS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220133679-A1 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME | IZUMI TECHNOLOGY, LLC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11312997-B2 | Methods and processes for non-invasive assessment of genetic variations | SEQUENOM, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220088201-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022051537-A1 | ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220054426-A1 | DUAL LANE COATING | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220047608-A1 | Method of Treatment and Pharmaceutical Composition for Morning Hypertension | Dharma Laboratories LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133679-A1 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME | ABCB11, ABCB1, ABCC1 | GABRA1 2948/4885GABRB1 894/4885GABRG2 1475/4885 |
| US-12606825-B2 | — | RPRD2, METTL16, RBM15 | GABRA1 3570/4885GABRB1 3182/4885GABRG2 2238/4885 |
| US-20260139249-A1 | GENE REPLACEMENT THERAPY FOR FOXG1 SYNDROME | FOXK1, PROX1, SCNN1G | GABRA1 2703/4885GABRB1 1776/4885GABRG2 601/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | GABRA1 3427/4885GABRB1 2785/4885GABRG2 2881/4885 |
| US-12553063-B2 | CAS13 family AAV vectors and uses thereof | CRBN, LDLR, CHLSN | GABRA1 4128/4885GABRB1 3913/4885GABRG2 4069/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | GABRA1 455/4885GABRB1 146/4885GABRG2 756/4885 |
| US-12570997-B2 | Factor H vectors and uses thereof | CFH, CFD, CFB | GABRA1 4804/4885GABRB1 4706/4885GABRG2 4284/4885 |
| US-20260027068-A1 | METHODS OF ADMINISTERING R-KETAMINE | SNCA, OPRD1, OPRK1 | GABRA1 171/4885GABRB1 199/4885GABRG2 934/4885 |
| US-12553036-B2 | GM3 synthase vectors and uses thereof | GPI, GALNT3, CHAT | GABRA1 1696/4885GABRB1 588/4885GABRG2 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.